Vertex Pharmaceuticals Inc. said yesterday regulators in the United States and Canada will speed their reviews of its drug candidate telaprevir, meaning the hepatitis C therapy could be approved months earlier than usual.
Vertex Pharmaceuticals Inc. said yesterday regulators in the United States and Canada will speed their reviews of its drug candidate telaprevir, meaning the hepatitis C therapy could be approved months earlier than usual.